Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Pipeline Review, H1 2019

Summary

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. The latest report Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H1 2019, outlays comprehensive information on the Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Glutamate receptor subunit epsilon-2 or N-methyl D-aspartate receptor subtype 2B (NMDAR2B or NR2B) is a protein encoded by the GRIN2B gene. It is mediated by glycine. It acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them resulting in an irreversible neuronal death.

The molecules developed by companies in Phase II, Phase I, Preclinical and Unknown stages are 2, 2, 6 and 1 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Dermatology which include indications Acute Ischemic Stroke, Autism, Burns, Cardiac Arrest, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Ischemic Stroke, Major Depressive Disorder, Myocardial Infarction, Neurodegenerative Diseases, Neuropathic Pain (Neuralgia), Obsessive-Compulsive Disorder, Orthostatic Hypotension, Pain, Subarachnoid Hemorrhage, Traumatic Brain Injury, Traumatic Spinal Cord Injury and Treatment Resistant Depression.

Furthermore, this report also reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B)

- The report reviews Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics and enlists all their major and minor projects

- The report assesses Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Overview
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Cadent Therapeutics Inc
Cerecor Inc
Johnson & Johnson
NeurOp Inc
Novartis AG
Shionogi & Co Ltd
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Drug Profiles
BMS-986163 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAD-8688 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ifenprodil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-0808 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neu-2000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-10679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rislenemdaz - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize NR2B for Depression - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize GRIN2B for Autism and Obsessive Compulsive Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize NMDA2B for Chronic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize NR2B for Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Dormant Products
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Discontinued Products
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Product Development Milestones
Featured News & Press Releases
Feb 15, 2019: Cerecor announces CERC-301 granted U.S. patent
Aug 01, 2018: Cerecor announces first patient enrolled in phase I trial for neurogenic orthostatic hypotension (noh) in Parkinson’s disease
Apr 12, 2018: NeurOp Initiates Phase 1 Clinical Trial of NMDA Receptor Inhibitor NP10679
Oct 17, 2017: Cadent Therapeutics Receives Milestone for the Initiation of Phase 1 Clinical Studies
Jul 24, 2017: NIH Awards NeurOp $3.5 Million to Support Phase 1 Clinical Trial of NMDA Inhibitor NP10679
Nov 29, 2016: Cerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder
Sep 21, 2016: Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder
May 16, 2016: GNT Pharma Receives IND Approval for Phase II Clinical Trial for Stroke Patients with Endovascular Treatment with First in Class Multi-Target Neuroprotection Drug Neu2000
Jan 19, 2016: Cerecor Announces Publication Describing Antidepressant Activity of CERC-301 in Preclinical Model
Sep 03, 2015: Cerecor Initiates Phase 2 Study for CERC-301, an Antidepressant Product Candidate with Potential for Rapid Onset of Effect
Mar 20, 2015: Cerecor Provides Update on CERC-301 Development in Major Depressive Disorder
Oct 03, 2014: Cerecor to Present at 13th Annual BIO Investor Forum
Dec 02, 2013: MedAvante Central Ratings Selected For Cerecor Investigational MDD Study
Nov 25, 2013: Cerecor Receives Fast Track Designation for CERC-301 for the Treatment of Major Depressive Disorder
Nov 08, 2013: Cerecor Announces Initiation of Phase 2 Study for CERC-301, an Oral Rapid-acting Antidepressant Candidate
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer